Optimisation of anti-psychotic therapeutics: a balancing act?
Schizophrenia is a complex and debilitating disorder. Although effective therapeutic strategies are available, these are not without problems and are not universally efficacious. In this issue of the British Journal of Pharmacology, a trio of papers describe the characterisation of a potential, novel anti-psychotic medication, F15063. This compound combines antagonism of dopamine D(2)-like receptors with agonism at 5-HT(1A) receptors. Based on in vitro and in vivo profiles, the authors suggest that this compound approaches the 'optimal balance' for activity at these receptor systems.
Lawrence
A J
AJ
Howard Florey Institute and Centre for Neuroscience, University of Melbourne, Parkville, Victoria, Australia. Andrew.Lawrence@hfi.unimelb.edu.au
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D003517:Cyclopentanes / Q000627:therapeutic use*; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D058825:Serotonin 5-HT1 Receptor Agonists
D014150:Antipsychotic Agents; D001572:Benzofurans; D001596:Benzylamines; D003517:Cyclopentanes; D065127:Dopamine D2 Receptor Antagonists; C518313:N-((2,2-dimethyl-2,3-dihydrobenzofuran-7-yloxy)ethyl)-3-(cyclopent-1-enyl)benzylamine; D058825:Serotonin 5-HT1 Receptor Agonists